Brief: Plus Therapeutics Presents Positive Clinical Trial Results At 2024 SNO/ASCO CNS Metastases Conference
13/08/2024 12:39
Aug 13 (Reuters) - Plus Therapeutics Inc PSTV.O :
* PLUS THERAPEUTICS PRESENTS POSITIVE CLINICAL TRIAL RESULTS
AT
THE 2024 SNO/ASCO CNS METASTASES CONFERENCE
* PLUS THERAPEUTICS INC: CNSIDE LEPTOMENINGEAL METASTASES
(LM)
FORSEE TRIAL MET KEY PRIMARY AND SECONDARY ENDPOINTS
* PLUS THERAPEUTICS INC: CNSIDE MORE THAN DOUBLED DIAGNOSTIC
SENSITIVITY VERSUS. GOLD STANDARD CEREBRAL SPINAL FLUID (CSF)
CYTOLOGY
Source text for Eikon: ID:nGNX4kjwtV
Further company coverage: PSTV.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer